This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC) (SCLC)

This study has been terminated.
(Unable to enroll adequate number of participants)
Information provided by (Responsible Party):
University of Florida Identifier:
First received: December 1, 2011
Last updated: May 15, 2015
Last verified: May 2015

This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung cancer in two fashions:

  1. to implement a prospective clinical trial to test the feasibility and efficacy of intralesional chemotherapy as consolidative therapy immediately following standard systemic chemotherapy and radiation therapy for patients with limited stage SCLC by comparing tumor growth and survival rates of the treatment group and compare the outcomes to historical controls
  2. to implement a prospective clinical trial to test the feasibility and efficacy as measured by tumor growth and survival rates of intralesional chemotherapy for patients with recurrent SCLC after standard treatment.

Condition Intervention Phase
Small Cell Lung Cancer Drug: Cisplatin Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by University of Florida:

Primary Outcome Measures:
  • Solid Tumor Growth After Completion of Interventional Bronchoscopies [ Time Frame: 18 months ]
    The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.

Secondary Outcome Measures:
  • Progression-free Survival [ Time Frame: 18 months ]
  • Overall Survival [ Time Frame: 5 years ]
    Subjects will be followed for 5 years or the remainder of the subject's life in order to determine long-term 5 year survival rates.

Enrollment: 4
Study Start Date: December 2011
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: patients with limited stage SCLC
Subjects with limited stage SCLC treated sequentially with cisplatin.
Drug: Cisplatin
40 mg in 40 mL of normal saline for each of 4 bronchoscopies
No Intervention: Historical Controls
No intervention

Detailed Description:
Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome measurements of tumor growth and survival will be compared to subjects receiving standard of care treatment only.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: Competent adult English speaking subjects

  • With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis,
  • With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction,
  • With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin

Exclusion Criteria:

  • Subjects who do not meet the inclusion criteria
  • Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01487499

United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
Principal Investigator: Michael A. Jantz, MD University of Florida
  More Information

Responsible Party: University of Florida Identifier: NCT01487499     History of Changes
Other Study ID Numbers: SCLC
Study First Received: December 1, 2011
Results First Received: March 16, 2015
Last Updated: May 15, 2015

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents processed this record on August 16, 2017